Asset Details
Do you wish to reserve the book?
Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease
Do you wish to request the book?
Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease
2005
Overview
Corticosteroid-resistant GVHD is difficult to manage and is associated with high morbidity and mortality. Cyclophosphamide (Cy) is an established immunosuppressive and cytotoxic drug widely used as part of pretransplant conditioning regimens. In a retrospective study of 15 patients who had not responded to corticosteroids (nine with acute GVHD, three with GVHD after donor leukocyte infusion, and three progressive chronic GVHD), pulse Cy at a median dose of 1 g/m(2) was very effective in the treatment of skin (100% response), liver (70% response), and the oral cavity (100% response). Severe intestinal GVHD responded poorly. The toxicity profile was acceptable, with manageable, short-term myelosuppression in some patients. The risk of opportunistic infections, mixed chimerism, relapses, or post-transplant lymphoproliferative disease was not increased. Overall survival was 57%, with median and maximum follow-up of 9 and 37 months, respectively. The cost of the drug was negligible, especially when compared to monoclonal antibodies. Pulse Cy requires further investigation in corticosteroid-resistant GVHD.
Publisher
Nature Publishing Group
Subject
/ Adrenal Cortex Hormones - pharmacology
/ Adult
/ Aged
/ Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
/ Biological and medical sciences
/ Bone marrow, stem cells transplantation. Graft versus host reaction
/ Cyclophosphamide - administration & dosage
/ Graft vs Host Disease - drug therapy
/ Graft vs Host Disease - mortality
/ Graft vs Host Disease - pathology
/ Hematopoietic Stem Cell Transplantation - adverse effects
/ Humans
/ Immunoproliferative diseases
/ Liver Diseases - drug therapy
/ Methods
/ Mouth Diseases - drug therapy
/ Patients
/ Skin Diseases - drug therapy
/ Steroids
/ Toxicity
/ Transfusions. Complications. Transfusion reactions. Cell and gene therapy
